Canagliflozin in Type 1 Diabetes: A Case Series of Patient Outcomes in a Diabetes Clinic.
作者信息
Roberts Tori Marie, Johnson June Felice, Vaughan Amy Grace
机构信息
Drake University College of Pharmacy and Health Sciences, Clinical Sciences Department, Des Moines, IA.
Drake University College of Business and Public Administration, Information Management and Business Analytics Department, Des Moines, IA.
出版信息
Diabetes Spectr. 2019 Feb;32(1):47-51. doi: 10.2337/ds17-0018.
Abstract
摘要
相似文献
1
Canagliflozin in Type 1 Diabetes: A Case Series of Patient Outcomes in a Diabetes Clinic.卡格列净用于1型糖尿病：糖尿病诊所患者结局的病例系列
Diabetes Spectr. 2019 Feb;32(1):47-51. doi: 10.2337/ds17-0018.
2
Real world clinical outcomes and patient characteristics for canagliflozin treated patients in a specialty diabetes clinic.在一家专科糖尿病诊所中，接受卡格列净治疗患者的真实世界临床结局和患者特征。
Curr Med Res Opin. 2017 Jan;33(1):77-84. doi: 10.1080/03007995.2016.1238354. Epub 2016 Oct 5.
3
Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA and Age.在一家专科糖尿病诊所接受卡格列净治疗的2型糖尿病患者的真实世界临床结局：按基线糖化血红蛋白和年龄进行的亚组分析。
Clin Ther. 2017 Jun;39(6):1123-1131. doi: 10.1016/j.clinthera.2017.04.006. Epub 2017 May 9.
4
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂坎格列净对 1 型糖尿病患者的血糖终点的影响：基于连续血糖监测和患者报告结局的评估。
Diabetes Care. 2017 Feb;40(2):171-180. doi: 10.2337/dc16-1353. Epub 2016 Nov 29.
5
Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes.卡格列净致 1 型糖尿病未识别患者范可尼综合征。
Am J Health Syst Pharm. 2019 Nov 13;76(23):1930-1933. doi: 10.1093/ajhp/zxz226.
6
Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials.卡格列净治疗对 2 型糖尿病患者健康相关生活质量的影响：来自随机对照试验的患者报告结局的汇总分析。
Patient. 2018 Jun;11(3):341-352. doi: 10.1007/s40271-017-0290-4.
7
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.卡格列净与 2 型糖尿病患者的肾脏结局：CANVAS 项目随机临床试验的结果。
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
8
CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.CANadian CAnagliflozin REgistry：加拿大卡格列净登记研究：卡格列净治疗加拿大临床实践中 2 型糖尿病患者的患者报告结局。
Can J Diabetes. 2019 Oct;43(7):464-471. doi: 10.1016/j.jcjd.2019.04.004. Epub 2019 Apr 16.
9
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
本文引用的文献
1
Erratum. Pharmacologic Approaches to Glycemic Treatment. Sec. 8. In . Diabetes Care 2017;40(Suppl. 1);S64-S74.勘误。血糖治疗的药理学方法。第8节。载于《糖尿病护理》2017年；40（增刊1）；S64 - S74。
Diabetes Care. 2017 Jul;40(7):985. doi: 10.2337/dc17-er07b. Epub 2017 May 18.
2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法（2017年执行摘要）的共识声明。
Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS. Epub 2017 Jan 17.
3
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂坎格列净对 1 型糖尿病患者的血糖终点的影响：基于连续血糖监测和患者报告结局的评估。
Diabetes Care. 2017 Feb;40(2):171-180. doi: 10.2337/dc16-1353. Epub 2016 Nov 29.
4
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.美国临床内分泌医师协会和美国内分泌学会关于钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与糖尿病酮症酸中毒相关性的立场声明
Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.
5
Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂卡格列净致 1 型糖尿病患者糖尿病酮症酸中毒
Diabetes Care. 2016 Apr;39(4):532-8. doi: 10.2337/dc15-1995.
6
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.恩格列净治疗1型糖尿病8周开放标签概念验证试验期间的日间血糖模式
PLoS One. 2015 Nov 6;10(11):e0141085. doi: 10.1371/journal.pone.0141085. eCollection 2015.
7
GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM.使用德康G4铂金连续血糖监测系统评估1型糖尿病患者中钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂卡格列净的血糖效应
Endocr Pract. 2016 Mar;22(3):315-22. doi: 10.4158/EP151016.OR. Epub 2015 Nov 2.
8
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂坎格列净作为胰岛素的附加疗法用于 1 型糖尿病患者的疗效和安全性。
Diabetes Care. 2015 Dec;38(12):2258-65. doi: 10.2337/dc15-1730. Epub 2015 Oct 20.
9
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.钠-葡萄糖共转运蛋白 2 抑制剂在 1 型糖尿病中的血糖控制作用：一项为期 8 周的开放标签概念验证试验结果。
Diabetes Care. 2014 May;37(5):1480-3. doi: 10.2337/dc13-2338. Epub 2014 Mar 4.
Zotero 插件